repaglinide

enUK

repaglinide

[rĕ-pag´lĭ-nīd] an oral hypoglycemic agent used in treatment of type 2 diabetes mellitus.

repaglinide

Gluconorm (CA), NovoNorm (UK), Prandin

Pharmacologic class: Meglitinide

Therapeutic class: Hypoglycemic

Pregnancy risk category C

Action

Inhibits alpha-glucosidases, enzymes that convert oligosaccharides and disaccharides to glucose. This inhibition lowers blood glucose level, especially in postprandial hyperglycemia.

Availability

Tablets: 0.5 mg, 1 mg, 2 mg

Indications and dosages

➣ Adjunct to diet and exercise in type 2 (non-insulin-dependent) diabetes mellitus uncontrolled by diet and exercise alone, or combined with metformin in type 2 diabetes mellitus uncontrolled by diet, exercise, and either repaglinide or metformin alone

Adults: 0.5 to 4 mg P.O. before each meal; may adjust at 1-week intervals based on blood glucose response. Maximum daily dosage is 16 mg.

Contraindications

• Hypersensitivity to drug or its components

• Diabetic ketoacidosis

• Type 1 (insulin-dependent) diabetes mellitus

• Administration with gemfibrozil

Precautions

Use cautiously in:

• renal or hepatic impairment; adrenal or pituitary insufficiency; stress caused by infection, fever, trauma, or surgery

• concurrent use of CYP2C8 inhibitors (such as trimethoprim, gemfibrozil, montelukast)

• concurrent use of CYP3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin)

• concurrent use of CYP3A4 or CYP2C8 inducers (such as rifampin, barbiturates, carbamazepine)

• elderly or malnourished patients

• pregnant or breastfeeding patients

• children.

Administration

• Give 15 to 30 minutes before meals. Administer two, three, or four times daily, if needed, to adapt to patient's meal pattern.

Adverse reactions

CNS: headache, paresthesia

CV: angina, chest pain

EENT: sinusitis, rhinitis

GI: nausea, vomiting, diarrhea, constipation, dyspepsia

GU: urinary tract infection

Metabolic: hyperglycemia, hypoglycemia

Musculoskeletal: joint pain, back pain

Respiratory: upper respiratory infection, bronchitis

Other: tooth disorder, hypersensitivity reaction

Interactions

Drug-drug. Barbiturates, carbamazepine, rifampin: decreased repaglinide blood level

Beta-adrenergic blockers, chloramphenicol, MAO inhibitors, nonsteroidal antiinflammatory drugs, probenecid, sulfonamides, warfarin: potentiation of repaglinide effects

Calcium channel blockers, corticosteroids, estrogens, hormonal contraceptives, isoniazid, phenothiazines, phenytoin, nicotinic acid, sympathomimetics, thyroid preparations: loss of glycemic control

Clarithromycin: increased repaglinide area under the curve and C_max

Cyclosporine: increased repaglinide plasma concentration

Erythromycin, ketoconazole, miconazole: decreased repaglinide metabolism, increased risk of hypoglycemia

Gemfibrozil, itraconazole: significantly increased repaglinide exposure

Simvastatin: increased repaglinide level

Drug-food. Any food: decreased drug bioavailability

Drug-herbs. Aloe gel (oral), bitter melon, chromium, coenzyme Q10, fenugreek, gymnema sylvestre, psyllium, St. John's wort: additive hypoglycemic effects

Glucosamine: poor glycemic control

Patient monitoring

• Monitor blood glucose and glycosylated hemoglobin levels.

• Monitor patient's meal pattern. Consult prescriber about adjusting dosage if patient adds or misses a meal.

• Assess for angina, shortness of breath, or other discomforts.

• Watch for signs and symptoms of bronchitis and upper respiratory, urinary, and EENT infections.

Patient teaching

• Tell patient to take 15 to 30 minutes before each meal.

• Instruct patient to monitor blood glucose level carefully. Teach him to recognize signs and symptoms of hypoglycemia and hyperglycemia.

• Advise patient to report signs and symptoms of infection.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.

repaglinide

(rĭ-păg′lə-nīd′)n. An oral hypoglycemic drug, C₂₇H₃₆N₂O₄, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.

repaglinide

NovoNorm^®, Prandin^® Endocrinology An oral nonsulfonylurea hypoglycemic for Pts with type 2 DM, whose hyperglycemia does not respond to diet and exercise

单词	repaglinide
释义	repaglinide enUK re·pag·li·nide R0156050 (rĭ-păg′lə-nīd′)n. An oral hypoglycemic drug, C₂₇H₃₆N₂O₄, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes. [re(lease) + pa(ncreas) + -glinide, antidiabetic drug suff. (shortening of -glitinide, from (me)gli(ti)nide, compound class to which it belongs).] Translations repaglinide enUK repaglinide [rĕ-pag´lĭ-nīd] an oral hypoglycemic agent used in treatment of type 2 diabetes mellitus. repaglinide Gluconorm (CA), NovoNorm (UK), Prandin *Pharmacologic class:* Meglitinide *Therapeutic class:* Hypoglycemic *Pregnancy risk category C* Action Inhibits alpha-glucosidases, enzymes that convert oligosaccharides and disaccharides to glucose. This inhibition lowers blood glucose level, especially in postprandial hyperglycemia. Availability Tablets: 0.5 mg, 1 mg, 2 mg Indications and dosages ➣ Adjunct to diet and exercise in type 2 (non-insulin-dependent) diabetes mellitus uncontrolled by diet and exercise alone, or combined with metformin in type 2 diabetes mellitus uncontrolled by diet, exercise, and either repaglinide or metformin alone Adults: 0.5 to 4 mg P.O. before each meal; may adjust at 1-week intervals based on blood glucose response. Maximum daily dosage is 16 mg. Contraindications • Hypersensitivity to drug or its components • Diabetic ketoacidosis • Type 1 (insulin-dependent) diabetes mellitus • Administration with gemfibrozil Precautions Use cautiously in: • renal or hepatic impairment; adrenal or pituitary insufficiency; stress caused by infection, fever, trauma, or surgery • concurrent use of CYP2C8 inhibitors (such as trimethoprim, gemfibrozil, montelukast) • concurrent use of CYP3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin) • concurrent use of CYP3A4 or CYP2C8 inducers (such as rifampin, barbiturates, carbamazepine) • elderly or malnourished patients • pregnant or breastfeeding patients • children. Administration • Give 15 to 30 minutes before meals. Administer two, three, or four times daily, if needed, to adapt to patient's meal pattern. Adverse reactions CNS: headache, paresthesia CV: angina, chest pain EENT: sinusitis, rhinitis GI: nausea, vomiting, diarrhea, constipation, dyspepsia GU: urinary tract infection Metabolic: hyperglycemia, hypoglycemia Musculoskeletal: joint pain, back pain Respiratory: upper respiratory infection, bronchitis Other: tooth disorder, hypersensitivity reaction Interactions Drug-drug. Barbiturates, carbamazepine, rifampin: decreased repaglinide blood level Beta-adrenergic blockers, chloramphenicol, MAO inhibitors, nonsteroidal antiinflammatory drugs, probenecid, sulfonamides, warfarin: potentiation of repaglinide effects Calcium channel blockers, corticosteroids, estrogens, hormonal contraceptives, isoniazid, phenothiazines, phenytoin, nicotinic acid, sympathomimetics, thyroid preparations: loss of glycemic control Clarithromycin: increased repaglinide area under the curve and C_max Cyclosporine: increased repaglinide plasma concentration Erythromycin, ketoconazole, miconazole: decreased repaglinide metabolism, increased risk of hypoglycemia Gemfibrozil, itraconazole: significantly increased repaglinide exposure Simvastatin: increased repaglinide level Drug-food. Any food: decreased drug bioavailability Drug-herbs. Aloe gel (oral), bitter melon, chromium, coenzyme Q10, fenugreek, gymnema sylvestre, psyllium, St. John's wort: additive hypoglycemic effects Glucosamine: poor glycemic control Patient monitoring • Monitor blood glucose and glycosylated hemoglobin levels. • Monitor patient's meal pattern. Consult prescriber about adjusting dosage if patient adds or misses a meal. • Assess for angina, shortness of breath, or other discomforts. • Watch for signs and symptoms of bronchitis and upper respiratory, urinary, and EENT infections. Patient teaching • Tell patient to take 15 to 30 minutes before each meal. • Instruct patient to monitor blood glucose level carefully. Teach him to recognize signs and symptoms of hypoglycemia and hyperglycemia. • Advise patient to report signs and symptoms of infection. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above. repaglinide (rĭ-păg′lə-nīd′)n. An oral hypoglycemic drug, C₂₇H₃₆N₂O₄, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes. repaglinide NovoNorm^®, Prandin^® Endocrinology An oral nonsulfonylurea hypoglycemic for Pts with type 2 DM, whose hyperglycemia does not respond to diet and exercise
随便看	european family medicine awareness european family therapy association european fan palm european fan palms european fantastic film festivals federation european fashion and textile export council european federalist movements european federation against hunting european federation for experimental morphology european federation for information technology in agriculture, food and the environment european federation for medical informatics european federation for medicinal chemistry european federation for pharmaceutical sciences european federation for psychiatric trainees european federation for retirement provision european federation for the advancement of anesthesia in dentistry european federation for the education of the children of occupational travellers european federation for welding, joining and cutting (formerly european welding federation european federation of accountants and auditors european federation of american football european federation of animal technologists european federation of auctioneers-appraisers european federation of audiology societies european federation of biotechnology european federation of black women business owners

repaglinide

re·pag·li·nide

repaglinide

repaglinide

repaglinide

Action

Availability

Indications and dosages

Contraindications

Precautions

Administration

Adverse reactions

Interactions

Patient monitoring

Patient teaching

repaglinide

repaglinide